SEC Form 4 · accession 0001104659-15-071608

Avalo Therapeutics, Inc. · AVTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Oct 20, 2015

Accepted (ET)

Oct 20, 2015 · 2:58 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001534120

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Oct 20, 2015	C	5,952	—	A	203,452	D
Common Stock^F1,F2	Oct 20, 2015	C	182,030	—	A	385,452	I	By Daniel Blech Trust DTD 8/3/2005

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F1	—	Oct 20, 2015	C	133,333	D	—	—	Common Stock	5,952	0	D
Series A Convertible Preferred Stock^F2,F1	—	Oct 20, 2015	C	4,077,475	D	—	—	Common Stock	182,030	0	I

F1The shares of Series A Convertible Preferred Stock (the "Series A Shares") automatically converted into Common Stock, on a 1-for-0.04464 basis and had no expiration date.
F2The reporting person disclaims beneficial ownership of the securities held by the Daniel Blech Trust DTD 8/3/2005 except to the extent of his pecuniary interest therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.